Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial
- PMID: 32302702
- DOI: 10.1016/j.jtho.2020.03.028
Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial
Abstract
Introduction: Cytotoxic agents have immunomodulatory effects, providing a rationale for combining atezolizumab (anti-programmed death-ligand 1 [anti-PD-L1]) with chemotherapy. The randomized phase III IMpower131 study (NCT02367794) evaluated atezolizumab with platinum-based chemotherapy in stage IV squamous NSCLC.
Methods: A total of 1021 patients were randomized 1:1:1 to receive atezolizumab+carboplatin+paclitaxel (A+CP) (n = 338), atezolizumab+carboplatin+nab-paclitaxel (A+CnP) (n = 343), or carboplatin+nab-paclitaxel (CnP) (n = 340) for four or six 21-day cycles; patients randomized to the A+CP or A+CnP arms received atezolizumab maintenance therapy until progressive disease or loss of clinical benefit. The coprimary end points were investigator-assessed progression-free survival (PFS) and overall survival (OS) in the intention-to-treat (ITT) population. The secondary end points included PFS and OS in PD-L1 subgroups and safety. The primary PFS (January 22, 2018) and final OS (October 3, 2018) for A+CnP versus CnP are reported.
Results: PFS improvement with A+CnP versus CnP was seen in the ITT population (median, 6.3 versus 5.6 mo; hazard ratio [HR] = 0.71, 95% confidence interval [CI]: 0.60-0.85; p = 0.0001). Median OS in the ITT population was 14.2 and 13.5 months in the A+CnP and CnP arms (HR = 0.88, 95% CI: 0.73-1.05; p = 0.16), not reaching statistical significance. OS improvement with A+CnP versus CnP was observed in the PD-L1-high subgroup (HR = 0.48, 95% CI: 0.29-0.81), despite not being formally tested. Treatment-related grade 3 and 4 adverse events and serious adverse events occurred in 68.0% and 47.9% (A+CnP) and 57.5% and 28.7% (CnP) of patients, respectively.
Conclusions: Adding atezolizumab to platinum-based chemotherapy significantly improved PFS in patients with first-line squamous NSCLC; OS was similar between the arms.
Keywords: Atezolizumab; Carboplatin; IMpower131; Nab-paclitaxel; Squamous NSCLC.
Copyright © 2020 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.
Comment in
-
IMpower 131: The Exception to the Rule.J Thorac Oncol. 2020 Aug;15(8):1258-1260. doi: 10.1016/j.jtho.2020.04.035. J Thorac Oncol. 2020. PMID: 32718531 No abstract available.
Similar articles
-
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.Lancet Oncol. 2019 Jul;20(7):924-937. doi: 10.1016/S1470-2045(19)30167-6. Epub 2019 May 20. Lancet Oncol. 2019. PMID: 31122901 Clinical Trial.
-
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol. 2020 Jan;21(1):44-59. doi: 10.1016/S1470-2045(19)30689-8. Epub 2019 Nov 27. Lancet Oncol. 2020. PMID: 31786121 Clinical Trial.
-
Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?J Immunother Cancer. 2018 Dec 3;6(1):135. doi: 10.1186/s40425-018-0427-6. J Immunother Cancer. 2018. PMID: 30509312 Free PMC article. Clinical Trial.
-
Atezolizumab (in Combination with Nab-Paclitaxel): A Review in Advanced Triple-Negative Breast Cancer.Drugs. 2020 Apr;80(6):601-607. doi: 10.1007/s40265-020-01295-y. Drugs. 2020. PMID: 32248356 Review.
-
Atezolizumab First-Line Combination Therapy: A Review in Metastatic Nonsquamous NSCLC.Target Oncol. 2019 Dec;14(6):759-768. doi: 10.1007/s11523-019-00686-w. Target Oncol. 2019. PMID: 31728860 Review.
Cited by
-
Efficacy and safety of camrelizumab-based comprehensive treatment for non-small cell lung cancer: a systematic review and meta-analysis.Ther Adv Med Oncol. 2024 Oct 4;16:17588359241284904. doi: 10.1177/17588359241284904. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 39376584 Free PMC article.
-
Exploring Demographic Representation and Reporting in Lung Cancer Clinical Trials with Canadian Sites from 2013 to 2023.Curr Oncol. 2024 Sep 17;31(9):5573-5598. doi: 10.3390/curroncol31090413. Curr Oncol. 2024. PMID: 39330041 Free PMC article. Review.
-
Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer Under-Represented by Clinical Trials.Curr Oncol. 2024 Sep 14;31(9):5498-5515. doi: 10.3390/curroncol31090407. Curr Oncol. 2024. PMID: 39330035 Free PMC article. Review.
-
Toxicity profile of camrelizumab-based immunotherapy in older adults with advanced cancer.Sci Rep. 2024 Aug 16;14(1):18992. doi: 10.1038/s41598-024-69944-w. Sci Rep. 2024. PMID: 39152261 Free PMC article.
-
Immune checkpoint inhibitors plus platinum-based chemotherapy compared to platinum-based chemotherapy with or without bevacizumab for first-line treatment of older people with advanced non-small cell lung cancer.Cochrane Database Syst Rev. 2024 Aug 13;8(8):CD015495. doi: 10.1002/14651858.CD015495. Cochrane Database Syst Rev. 2024. PMID: 39136258 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous